BCL2 and head and neck squamous cell carcinoma: Park et al. reported overcoming cisplatin resistance by downregulating Bcl-2 in HNSCC by modulating tristetraprolin (TTP) expression (19), the mechanisms underlying linking Bcl-2 overexpression and therefore reduced sensitivity to cisplatin in HNSCC have not been reported.